RATIONALE: Activation of liver X receptors (LXRs) inhibits the progression of atherosclerosis and promotes regression of existing lesions. In addition, LXRα levels are high in regressive plaques. Macrophage arginase 1 (Arg1) expression is inversely correlated with atherosclerosis progression and is markedly decreased in foam cells within the lesion. OBJECTIVE: To investigate LXRα regulation of Arg1 expression in cultured macrophages and atherosclerotic regressive lesions. METHODS AND RESULTS: We found that Arg1 expression is enhanced in CD68+ cells from regressive versus progressive lesions in a murine aortic arch transplant model. In cultured macrophages, ligand-activated LXRα markedly enhances basal and interleukin-4-induced Arg1 mRNA and protein expression as well as promoter activity. This LXRα-enhanced Arg1 expression correlates with a reduction in nitric oxide levels. Moreover, Arg1 expression within regressive atherosclerotic plaques is LXRα-dependent, as enhanced expression of Arg1 in regressive lesions is impaired in LXRα-deficient CD68+ cells. LXRα does not bind to the Arg1 promoter but instead promotes the interaction between PU.1 and interferon regulatory factor (IRF)8 transcription factors and induces their binding of a novel composite element. Accordingly, knockdown of either IRF8 or PU.1 strongly impairs LXRα regulation of Arg1 expression in macrophage cells. Finally, we demonstrate that LXRα binds the IRF8 locus and its activation increases IRF8 mRNA and protein levels in these cells. CONCLUSIONS: This work implicates Arg1 in atherosclerosis regression and identifies LXRα as a novel regulator of Arg1 and IRF8 in macrophages. Furthermore, it provides a unique molecular mechanism by which LXRα regulates macrophage target gene expression through PU.1 and IRF8.
RATIONALE: Activation of liver X receptors (LXRs) inhibits the progression of atherosclerosis and promotes regression of existing lesions. In addition, LXRα levels are high in regressive plaques. Macrophage arginase 1 (Arg1) expression is inversely correlated with atherosclerosis progression and is markedly decreased in foam cells within the lesion. OBJECTIVE: To investigate LXRα regulation of Arg1 expression in cultured macrophages and atherosclerotic regressive lesions. METHODS AND RESULTS: We found that Arg1 expression is enhanced in CD68+ cells from regressive versus progressive lesions in a murine aortic arch transplant model. In cultured macrophages, ligand-activated LXRα markedly enhances basal and interleukin-4-induced Arg1 mRNA and protein expression as well as promoter activity. This LXRα-enhanced Arg1 expression correlates with a reduction in nitric oxide levels. Moreover, Arg1 expression within regressive atherosclerotic plaques is LXRα-dependent, as enhanced expression of Arg1 in regressive lesions is impaired in LXRα-deficient CD68+ cells. LXRα does not bind to the Arg1 promoter but instead promotes the interaction between PU.1 and interferon regulatory factor (IRF)8 transcription factors and induces their binding of a novel composite element. Accordingly, knockdown of either IRF8 or PU.1 strongly impairs LXRα regulation of Arg1 expression in macrophage cells. Finally, we demonstrate that LXRα binds the IRF8 locus and its activation increases IRF8 mRNA and protein levels in these cells. CONCLUSIONS: This work implicates Arg1 in atherosclerosis regression and identifies LXRα as a novel regulator of Arg1 and IRF8 in macrophages. Furthermore, it provides a unique molecular mechanism by which LXRα regulates macrophage target gene expression through PU.1 and IRF8.
Authors: Chaitra Marathe; Michelle N Bradley; Cynthia Hong; Felix Lopez; Carlos M Ruiz de Galarreta; Peter Tontonoz; Antonio Castrillo Journal: J Biol Chem Date: 2006-08-30 Impact factor: 5.157
Authors: Serena Ghisletti; Wendy Huang; Sumito Ogawa; Gabriel Pascual; Mu-En Lin; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass Journal: Mol Cell Date: 2007-01-12 Impact factor: 17.970
Authors: Murray C H Clarke; Nichola Figg; Janet J Maguire; Anthony P Davenport; Martin Goddard; Trevor D Littlewood; Martin R Bennett Journal: Nat Med Date: 2006-08-06 Impact factor: 53.440
Authors: Tetyana V Pedchenko; Gye Young Park; Myungsoo Joo; Timothy S Blackwell; John W Christman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-09 Impact factor: 5.464
Authors: Daniel Teupser; Ralph Burkhardt; Wolfgang Wilfert; Ivonne Haffner; Klaus Nebendahl; Joachim Thiery Journal: Arterioscler Thromb Vasc Biol Date: 2005-11-10 Impact factor: 8.311
Authors: Eugene Trogan; Jonathan E Feig; Snjezana Dogan; George H Rothblat; Véronique Angeli; Frank Tacke; Gwendalyn J Randolph; Edward A Fisher Journal: Proc Natl Acad Sci U S A Date: 2006-03-01 Impact factor: 11.205
Authors: Chaowei Wu; Maryem A Hussein; Elina Shrestha; Sarah Leone; Mohammed S Aiyegbo; W Marcus Lambert; Benoit Pourcet; Timothy Cardozo; Jan-Ake Gustafson; Edward A Fisher; Ines Pineda-Torra; Michael J Garabedian Journal: Mol Cell Biol Date: 2015-03-30 Impact factor: 4.272
Authors: Roel P H De Maeyer; Rachel C van de Merwe; Rikah Louie; Olivia V Bracken; Oliver P Devine; Daniel R Goldstein; Mohib Uddin; Arne N Akbar; Derek W Gilroy Journal: Nat Immunol Date: 2020-04-06 Impact factor: 25.606
Authors: Jinsam Chang; Shankar Thangamani; Myung H Kim; Benjamin Ulrich; Sidney M Morris; Chang H Kim Journal: Eur J Immunol Date: 2013-02-14 Impact factor: 5.532